NeuroSolutions Enters into a Collaboration Agreement with Gentronix
News Jun 08, 2006
Pursuant to the agreement both companies will seek to assess the genetic toxicology of NSL-105 by using GreenScreen, Gentronix’s commercially available yeast-based assay.
In particular, the assay’s specificity is demonstrated by the extremely low incidence of false positives compared to other available tests.
NeuroDiscovery Chairman, Dr Mark Treherne said, "We are delighted to collaborate with Gentronix and this agreement will provide us with a significant opportunity to accelerate the development of NSL-105 to build an in-depth pipeline of innovative products for the treatment of a variety of painful medical conditions."
"Recent forecasts predict a global market value for neuropathic pain treatments of over US$4 billion by 2007."
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
Tuberculosis: Pharmacists Develop Substance to Counteract Antimicrobial ResistanceNews
Antimicrobial resistance is on the rise worldwide. This is becoming a problem for infectious diseases like tuberculosis as there are only a few active substances available to combat such diseases. Pharmacists have now found a way to increase the efficacy of a common tuberculosis agent while, at the same time, reducing resistance to it.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018